Stockscreener 앱 받기
20.86
2.81%
0.57
시간 외 거래:
20.91
0.05
+0.24%
전일 마감가:
$20.29
열려 있는:
$20.33
하루 거래량:
889.25K
Relative Volume:
0.86
시가총액:
$1.07B
수익:
$75.04M
순이익/손실:
$-167.18M
주가수익비율:
-6.5255
EPS:
-3.1967
순현금흐름:
$-168.39M
1주 성능:
+8.25%
1개월 성능:
+23.14%
6개월 성능:
+74.71%
1년 성능:
+73.54%
1일 변동 폭
$20.02
$20.91
1주일 범위
$19.14
$20.91
52주 변동 폭
$9.83
$21.30
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
20.86 | 1.04B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.85 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 재확인 | Needham | Buy |
| 2026-01-06 | 재확인 | Needham | Buy |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data - Sahm
Inflation Data: Is KalVista Pharmaceuticals Inc subject to activist investor interestDay Trade & Growth Focused Investment Plans - baoquankhu1.vn
Market Moves: Is KalVista Pharmaceuticals Inc impacted by rising ratesWeekly Investment Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
KalVista Pharmaceuticals Inc (HAM:4XC1) Valuation - GuruFocus
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Behavioral Patterns of KALV and Institutional Flows - Stock Traders Daily
Investor Mood: Is KalVista Pharmaceuticals Inc forming higher highs and higher lows2026 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Merger Talk: Will KalVista Pharmaceuticals Inc face regulatory challenges2026 Price Momentum & High Accuracy Investment Signals - baoquankhu1.vn
Ekterly pill may change how families treat HAE attacks in young children - Angioedema News
Death Cross: Can KalVista Pharmaceuticals Inc expand its profit marginsShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Breakout Zone: Can KalVista Pharmaceuticals Inc deliver consistent dividendsProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - joplinglobe.com
KALV PE Ratio & Valuation, Is KALV Overvalued - Intellectia AI
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV) - Seeking Alpha
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Big Picture: Will KalVista Pharmaceuticals Inc face regulatory challengesMarket Performance Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold - marketbeat.com
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next - Sahm
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - Sahm
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year HighShould You Buy? - MarketBeat
KALV Should I Buy - Intellectia AI
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance
KalVista Pharmaceuticals Stock: Positive Pediatric Trial Data Positions KALV for HAE Market Expansio - AD HOC NEWS
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista reports interim data on pediatric HAE treatment trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - BioSpace
(KALV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
KalVista (KALV) Announces Positive Interim Results from KONFIDEN - GuruFocus
KalVista Announces Positive Interim Data for Pediatric HAE Treatment - National Today
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data - The National Law Review
KalVista reports interim data on pediatric HAE treatment trial - Investing.com
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings - MarketBeat
KalVista Pharmaceuticals Inc Stock Historical Valuations | HAM:4XC1 - GuruFocus
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen - MarketBeat
Venrock healthcare sells KalVista (KALV) shares for $3.69 million - Investing.com UK
Venrock healthcare sells KalVista (KALV) shares for $3.69 million By Investing.com - Investing.com South Africa
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - stocktitan.net
KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade - MarketBeat
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kalvista Pharmaceuticals Inc 주식 (KALV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Mar 26 '26 |
Sale |
18.28 |
39,986 |
730,822 |
5,089,354 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Mar 09 '26 |
Sale |
16.08 |
6,693 |
107,633 |
451,815 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 23 '26 |
Sale |
15.57 |
5,354 |
83,345 |
138,983 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 23 '26 |
Sale |
15.57 |
10,034 |
156,197 |
442,883 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 23 '26 |
Sale |
15.57 |
4,347 |
67,669 |
226,701 |
| Sweeny Nicole | Chief Commercial Officer |
Feb 23 '26 |
Sale |
15.57 |
3,975 |
61,878 |
47,003 |
| Piekos Brian | Chief Financial Officer |
Feb 23 '26 |
Sale |
15.57 |
1,767 |
27,507 |
13,762 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,038 |
15,570 |
429,667 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,163 |
17,445 |
133,087 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,109 |
16,635 |
224,173 |
2.69%
0.25%
자본화:
|
볼륨(24시간):